Tempus Wealth Planning LLC Buys New Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

Tempus Wealth Planning LLC purchased a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 5,550 shares of the company’s stock, valued at approximately $346,000.

Several other institutional investors and hedge funds have also bought and sold shares of TMDX. State of Alaska Department of Revenue purchased a new position in TransMedics Group during the third quarter valued at approximately $2,560,000. Charles Schwab Investment Management Inc. grew its stake in shares of TransMedics Group by 2.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after purchasing an additional 6,634 shares during the period. Zacks Investment Management purchased a new position in shares of TransMedics Group during the 3rd quarter valued at approximately $1,607,000. Vaughan Nelson Investment Management L.P. lifted its stake in shares of TransMedics Group by 24.3% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after purchasing an additional 64,360 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in TransMedics Group by 665.1% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock worth $11,716,000 after buying an additional 64,872 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the transaction, the insider now owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 7.00% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on TMDX. Canaccord Genuity Group decreased their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research report on Wednesday, December 11th. Oppenheimer restated an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research report on Tuesday, December 3rd. Finally, TD Cowen decreased their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research report on Monday, November 18th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Price Performance

TransMedics Group stock opened at $72.14 on Wednesday. The company has a fifty day simple moving average of $67.09 and a 200-day simple moving average of $111.20. The firm has a market capitalization of $2.42 billion, a price-to-earnings ratio of 76.75 and a beta of 2.12. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.